Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007 Mar; 21(3):489-93.
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents
-
Benzamides
-
Chromatography, High Pressure Liquid
-
Codon
-
DNA Mutational Analysis
-
DNA, Neoplasm
-
Drug Resistance, Neoplasm
-
Female
-
Follow-Up Studies
-
Fusion Proteins, bcr-abl
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Male
-
Middle Aged
-
Mutant Proteins
-
Mutation
-
Piperazines
-
Protein Kinase Inhibitors
-
Protein Structure, Tertiary
-
Pyrimidines
-
Remission Induction
-
Reverse Transcriptase Polymerase Chain Reaction
-
RNA, Messenger
-
RNA, Neoplasm
-
Treatment Refusal